|
Found 59 result(s) FROM 1963 pages containing the term 'bisphosphonates'.
Friday Mar 12, 2010
Long-term Bisphosphonate Use May Actually Increase Fracture Risk
The osteoporosis drugs may boost bone quantity at the expense of bone quality, eventually weakening users' bones...
Monday Oct 19, 2009
Denosumab Approval Faces Delay
FDA-watchers predict that the agency will miss the October 19th target set for denosumab approval by as much as 3 months...
Thursday Aug 27, 2009
Study: Hip Fracture Rates On the Decline in Canada
Hip fracture rates in Canada have been declining since 1985, with a more rapid drop between 1996 and 2005...
Wednesday Jun 03, 2009
DHEA Intensifies Calcium, Vitamin D Effect on BMD
Adding DHEA to calcium and vitamin D significantly increases spine BMD in older women (but not in men) and might be a good thing, provided the women don't have family cancer risk and don't need to pass any sports doping tests...
Wednesday Jan 07, 2009
Study Links Osteoporosis Drugs to Jaw Trouble
People taking oral osteoporosis drugs may have a higher risk of developing jaw trouble than previously thought...
Thursday Nov 20, 2008
FDA Says Bisphosphonates Do Not Cause Atrial Fibrillation
The FDA has concluded that there is no causal link between the use of bisphosphonates and atrial fibrillation...
Thursday Nov 13, 2008
H. pylori Suspected in Oral Bisphosphonate Intolerance, SSc Stomach Problems
Helicobacter pylori infects nearly half of patients who cannot tolerate oral bisphosphonates and over 80% of systemic sclerosis patients. Treating H. pylori might reduce GI problems and increase treatment options in these and other rheumatoid conditions...
Wednesday Aug 20, 2008
Zoledronic Acid Prevents Chemo-Induced Bone Loss in Premenopausal Women With Breast Cancer
As the population of breast cancer survivors grows, the risks of life after cancer treatment are becoming a major concern. One risk is bone loss caused by chemotherapy, and phase III data show that a dose of zoledronic acid every 3 months during chemotherapy can prevent this problem in premenopausal women with breast cancer...
Wednesday Aug 06, 2008
Statins May Help Bone Healing
Statins may improve bone healing, according to new research in an animal model of neurofibromatosis type 1 (NF1)…
Thursday Jul 17, 2008
Drugs to Build Bones May Weaken Them
A small group of people taking bisphosphonates for 5 or more years to treat osteoporosis have had their bones weakened by the drugs that are intended to promote better bone health…
Wednesday Jun 25, 2008
Endocrinologists Wrestle With Question of How Long to Continue Bisphosphonate Therapy for Osteoporosis
The jury is still out when it comes to how long bisphosphonate therapy should be continued…
Monday Jun 23, 2008
More Zoledronic Acid Fracture Reduction Data Reported at Endocrine Society Meeting
Yearly infusions of zoledronic acid 5 mg reduced fractures and increased bone mineral density (BMD) when administered with or without concomitant osteoporosis therapy…
Thursday Jun 19, 2008
Influence of Musculoskeletal Conditions on Oral Health Among Older Adults
Several musculoskeletal diseases negatively influence oral health, but damage can be minimized with simple and inexpensive measures…
Monday Jun 09, 2008
Genta Announces Phase I Clinical Trial Results for G4544, an Oral Formulation of Gallium Nitrate, a Novel Potent Drug for Bone Disease
Results from the phase I clinical trial of G4544 showed that the drug was well-tolerated and that blood levels were achieved in a range known to be clinically bioactive...
Thursday May 29, 2008
Bone Drug Might Prevent Breast Cancer Spread
Zoledronic acid (Zometa®) may help prevent the spread of locally advanced breast cancer into the bone marrow…
Tuesday May 27, 2008
Factors Associated With Osteonecrosis of the Jaw Among Bisphosphonate Users
Researchers found a multitude of factors associated with the development of osteonecrosis of the jaw among patients taking bisphosphonates for an indication other than cancer...
Friday May 23, 2008
Iatrogenic Problems Reported in Low Back Pain, Osteoporosis Patients at AACE Meeting
Cases of iatrogenic Cushing's syndrome (CS) from intra-articular triamcinolone and iatrogenic hypercalcemia from combined teriparatide-hydrochlorothiazide were reported at the American Association of Clinical Endocrinologists 2008 meeting...
Tuesday Apr 29, 2008
Alendronate Linked to Atrial Fibrillation
A case-control study reports that women who have used alendronate are nearly twice as likely to develop atrial fibrillation as those who have never used bisphosphonates...
Wednesday Apr 02, 2008
DEXA Scans, Serum Testosterone, Vitamin D Tests Urged for Men Over 70
Osteoporosis in men is a common problem and requires more aggressive diagnosis, treatment, and monitoring of response...
Tuesday Mar 11, 2008
AAOS Researchers Warn of Alendronate Fracture Risk
Two studies reported at the AAOS meeting warned of a possible increase in risk of low-energy or stress fractures associated with long-term use of alendronate...
Thursday Feb 28, 2008
Acceleron, Celgene to Collaborate on Anabolic Bone Agent ACE-011, a Decoy Activin Receptor, for Cancer-Related Bone Loss
Acceleron Pharma and Celgene Corp announced a worldwide strategic collaboration for the development and commercialization of ACE-011, a novel bone-forming compound for the treatment of cancer-related bone loss...
Thursday Jan 31, 2008
Alendronate Decreases TRACP 5b Activity in Osteoarthritic Bone
Bisphosphonates may reduce TRACP 5b activity in the intertrochanteric area of the femoral head, suggesting that they are most effective in areas of well-supplied bone...
Tuesday Jan 08, 2008
FDA Warns of Severe Bone, Joint, Muscle Pain Linked to Bisphosphonates
FDA warning highlights "severe and sometimes incapacitating" musculoskeletal pain in patients taking bisphosphonates...
Monday Nov 26, 2007
Teriparatide Builds More Bone Than Alendronate in Steroid-Caused Osteoporosis
Teriparatide built more bone mass and prevented more vertebral fractures than alendronate in the first head-to-head study of the two drugs for glucocorticoid-induced osteoporosis...
Friday Oct 12, 2007
Novartis' Aclasta® Receives EU Approval as First Once-Yearly Treatment for Postmenopausal Osteoporosis
Novartis Pharmaceuticals AG announced that Aclasta® (zoledronic acid 5 mg) has received EU approval as the first once-yearly treatment for women with postmenopausal osteoporosis...
Thursday Oct 04, 2007
Celera Receives Clinical Milestone Payment Based on Merck's Advancement of Odanacatib, a Cathepsin K Inhibitor; Phase III Trial for Osteoporosis Initiated
Celera, an Applera Corp business, announced a clinical milestone payment of $2 million from Merck & Co, Inc, under the cathepsin K inhibitor collaboration agreement between the companies...
Thursday Aug 30, 2007
Vitamin K2 Supplements Protect Bone Architecture
Three years of dietary supplementation with vitamin K2 maintained bone strength and architecture despite having little effect on BMD...
Monday Aug 20, 2007
Novartis' Once-Yearly Reclast® Receives US FDA Approval for Women With Postmenopausal Osteoporosis
Novartis Pharmaceuticals Corp announced that its once-yearly, 15-minute infusion treatment of Reclast® (zoledronic acid) injection has been approved by the US FDA for women with postmenopausal osteoporosis...
Tuesday Jul 24, 2007
Novartis Receives Positive Opinion Supporting EU Approval for Aclasta® as the First Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
Novartis Pharmaceuticals AG announced that it has been informed by the European Medicines Agency that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on the marketing application for the use of Aclasta®.
Monday May 21, 2007
Risedronate Bests Alendronate for Fracture Reduction in REAL-World Setting
Patients receiving once-weekly risedronate have lower rates of hip and nonvertebral fractures during their first year of therapy than their counterparts who receive once-weekly alendronate...
Wednesday May 02, 2007
Yearly Injection of Zoledronic Acid Cuts Spine Fracture Risk by 70%
A single intravenous 5-mg dose of zoledronic acid (Reclast®), given once yearly, can significantly reduce the risk of vertebral, hip,and other fractures, but its major advantage may lie in the ease of administration…
Wednesday Mar 21, 2007
BioMimetic Receives Orphan Drug Designation for rhPDGF-BB Treatment of Osteonecrosis of the Jaw
BioMimetic Therapeutics, Inc, an emerging leader in developing and commercializing bioactive drug-device combination drugs to heal musculoskeletal injuries and disease, including periodontal, orthopaedic, spine and sports injuries, announced that it has received orphan drug designation from the US FDA for its protein therapeutic, recombinant human platelet-derived growth factor (rhPDGF-BB)...
Monday Jan 22, 2007
Merrion Reports Positive Clinical Results for Osteoporosis Drug MER 103, An Innovative Dosage Form of Alendronate (Fosamax); Absorbed More Effectively and Improved Dosing Ritual vs Fosamax
Merrion Pharmaceuticals Ltd, a privately-held international specialty pharmaceutical company engaged in the development of improved oral dosage forms of drugs that have poor bioavailability, announced the successful completion of a phase II clinical pharmacology study of MER 103.
Thursday Jan 18, 2007
New Treatments Rocked Rheumatology in 2006
New treatment options have advanced rheumatology care in 2006, but lupus remains an unsolved problem, and CIAOMed Editorial Board members expect economic issues to greatly impact rheumatology practice in 2007...
Wednesday Jan 17, 2007
Rheumatologists May Be Doing Better at Treating Osteoporosis in RA Patients
Management of osteoporosis in rheumatoid arthritis (RA) patients has improved modestly since 1999 (at least in one large academic practice)...
Thursday Nov 30, 2006
Low Risk of Jaw Osteonecrosis Seen With Bisphosphonates for Osteoporosis
Osteonecrosis of the jaw has emerged as an unanticipated problem associated with bisphosphonate treatment in cancer patients, but is seldom a significant risk at the doses used for osteoporosis...
Wednesday Nov 15, 2006
Once-Yearly Zoledronic Acid Injection Reduces Fracture Risk, Improves Bone Structure in Postmenopausal Women With Osteoporosis
Once-yearly injections of zoledronic acid 5 mg reduces fracture risk, improves bone mineral density, and improves bone structure in women with osteoporosis... Black DM, Recker RR. Presented at ACR 2006 Meeting.
Tuesday Oct 10, 2006
ASBMR Convenes International Task Force on Jaw Osteonecrosis, Issues Interim Guidelines for Osteoporosis Patients
Reacting to multiple reports of jaw osteonecrosis in patients treated with bisphosphonates, the ASBMR has convened an international task force to address this "emerging and urgent clinical problem" and has issued interim clinical recommendations... Shane E, et al. JBMR. 2006;21:1503-1505.
Monday Sep 18, 2006
Novartis' Once-Yearly Reclast Investigational Infusion Osteoporosis Treatment Significantly Cuts Risk of Spine and Hip Fractures in Postmenopausal Women
Novartis Pharmaceuticals Corporation announced that phase III data presented at the 28th Annual meeting of the American Society for Bone and Mineral Research (ASBMR), September 15–19, 2006, in Philadelphia, Pa, demonstrated that its investigational, once-yearly bisphosphonate 15-minute infusion treatment, Reclast® (zoledronic acid) 5 mg, was highly effective at reducing the incidence of bone fracture in women with postmenopausal osteoporosis across the most common fracture sites—hip, spine, and nonspine (with the exception of face, fingers, and toes)—with sustained effect over 3 years.
Thursday Aug 31, 2006
Alendronate Better Than Alfacalcidol for Preventing GC-Induced Bone Loss
A randomized, double-blind clinical trial finds that alendronate is significantly better than alfacalcidol at preventing glucocorticoid-induced bone loss and reducing fracture risk...
Monday Jul 31, 2006
Steroids Cause Osteoporosis by Blocking Osteoclast Role in Bone Remodeling
The bone loss caused by glucocortocoid treatment is due to steroid-induced changes in osteoclasts, which then fail to create the conditions osteoblasts need to accomplish new bone formation....Kim H-J, et al. J Clin Invest. 2006 July 27 [Epub ahead of print].
Tuesday May 30, 2006
Give Bisphosphonates and Teriparatide Sequentially, Not Together
Alendronate reduces the ability of once-daily teriparatide to stimulate new bone formation in osteoporotic men; the two drugs therefore should not be given concurrently... Finkelstein JS, et al. J Clin Endocrinol Metab. 9 May 2006; [Epub ahead of print]
Monday May 22, 2006
Second Year of FACT Trial Confirms Alendronate Advantage Over Risedronate for Preventing Bone Loss
Twenty-four-month data show that alendronate surpasses risedronate in reducing the risk of bone loss in postmenopausal women with osteoporosis... Bonnick S, et al. Clin Endocrin Metab. 24 April 2006; [Epub ahead of print]
Thursday May 11, 2006
Adding Zoledronic Acid Improves MTX Efficacy in Early RA
Zoledronic acid added to standard methotrexate treatment reduced the progression of MRI hand and wrist erosions by 61% in patients with early RA, apparently by inhibiting osteoclast activity... Jarrett AJ, et al. Arthritis Rheum. 2006;54:1410-1414.
Tuesday May 09, 2006
Calcium Supplements Don't Reduce Fracture Risk Unless Patients Take Them
Supplementation with calcium carbonate tablets is ineffective at reducing fracture rates in the ambulatory elderly as a mass public health intervention due to poor long-term compliance, but the supplements are effective in patients who actually take them... Prince RL, et al. Arch Intern Med. 2006;166:869-875.
Thursday Mar 02, 2006
Denosumab Shows Promise in Phase II Study of Bone Mineral Density
Twice yearly injections of denosumab (previously known as AMG 162) significantly increased bone mineral density in the total hip, lumbar spine, distal 1/3 radius, and total body of postmenopausal women compared with placebo... McClung MR, et al. N Engl J Med. 2006;354:821-831.
Friday Jan 20, 2006
Patients with Chronic Skin Disease Who Require Long-Term Corticosteroids Not Receiving Bisphosphonates
Most patients who receive prolonged oral corticosteroids for chronic skin diseases such as pemphigus vulgaris and cutaneous lupus erythematosus are not receiving bisphosphonates... Liu RH, et al. Arch Dermatol. 2006;142:37-41.
Wednesday Jan 18, 2006
P&G and Sanofi-Aventis File Lawsuit Against Roche and GSK Alleging False and Misleading Advertising for Osteoporosis Drug Boniva®
Procter & Gamble Pharmaceuticals and Sanofi-Aventis US, LLC, co-marketers of Actonel® (risedronate sodium) tablets, announced that they have filed...
Friday Dec 02, 2005
New Study Indicates Fear of Addiction Among Other Surprising Reasons for Poor Adherence to Bisphosphonate Therapy
While lack of adherence to bisphosphonates is well-known, recent research has shed new light on possible causes, including difficulties in following prescribing instructions, frequency of dosing schedules, potential drug-drug interactions, and fear of addiction… Presented at: Annual Meeting of the American College of Rheumatology; San Diego, Calif. Abstract 625.
Thursday Sep 29, 2005
Long-Term Bisphosphonate Therapy Remains an Unresolved Issue
Despite concerns about long-term bisphosphonate therapy resulting in the continued suppression of bone turnover and inhibition of normal repair and replacement of damaged bone, recent clinical trials suggest that treatment for up to 10 years is not harmful ... Presented at: 27th Annual Meeting of the American Society for Bone and Mineral Research; September 23-25, 2005; Nashville, Tenn.
Tuesday Sep 27, 2005
Novel Method of Upfront Loading of Bisphosphonates Found to Improve Spinal Bone Mineral Density and Reduce Fractures
Upfront loading of oral or intravenous bisphosphonates followed by maintenance dosing may enhance the ability of these agents to reduce fracture risk compared with currently used dosing regimens... Presented at: 27th Annual Meeting of the American Society for Bone and Mineral Research; September 23-27, 2005; Nashville, Tennessee. Abstract M369.
Tuesday Sep 13, 2005
Two New Treatments Show Promise in Paget's Disease
Zoledronic acid and osteoprotegerin found to be promising new therapies for the management of Paget's disease... Reid IR, et al. N Engl J Med. 2005;353:898-908; Cundy MD, et al. N Engl J Med. 2005;353:918-923.
Monday May 02, 2005
Vitamin D and Calcium May Not Be Effective for Preventing Fractures
Taken together, two studies suggest an earlier role for antiresorptive drugs in fracture prevention...Grant AM, Anderson FH. Lancet. April 28, 2005; [Epub ahead of print].
Wednesday Dec 15, 2004
Novel Class of Bone Resorption Inhibitors Is Identified
Newly identified biphenyl derivatives, which are shown to inhibit osteoclastic bone resorption in vitro and prevent ovariectomy-induced bone loss in vivo, may have potential therapeutic advantages over bisphosphonates in the treatment of diseases such as osteoporosis, Paget's disease, and cancer-associated bone disorders....van Hof RJ, et al. J Bone Miner Res. 2004;19:1651-1660.
Monday Nov 15, 2004
EPIC Study: Alendronate's Benefits for Osteoporosis Prevention Continue Up to 6 Years
Therapy with the bisphosphonate is effective long-term in preserving bone mineral density in postmenopausal women, and should serve as a promising strategy for the prevention of osteoporosis in the post-HRT era& McClung MR, et al. J Clin Endocrinol Metab. 2004;89:4879-4885.
Tuesday Oct 12, 2004
Few Patients Undergo Screening or Receive Treatment for Glucocorticoid-induced Osteoporosis
Despite evidence of rapid bone loss associated with chronic oral steroid use, fewer than 25% of men and 50% of women undergo screening or receive treatment for glucocorticoid-induced osteoporosis... Curtis JR, et al. J Bone Miner Res. 2004;19(suppl 1):S30. Abstract 1114.
Monday Oct 11, 2004
Vitamin D Deficiency May Diminish Effectiveness of Osteoporosis Therapy
Recently released clinical trials data underscore the impact of vitamin D deficiency in at-risk populations, and the importance of the vitamin in strengthening the effects of osteoporosis therapy... Holick MF, et al. J Bone Miner Metab. 2004;19 (suppl 1):S342. Abstract SU583.
Thursday Oct 07, 2004
Emerging Role of Bone Turnover Markers in Clinical Management of Osteoporotic Patients
According to a leading authority at the annual meeting of The American Society for Bone and Mineral Research, markers of bone turnover can be a potentially valuable component of the overall management strategy for osteoporosis... (Johnell O, et al. Osteoporos Int. 2002;13:523-526; Eastell R, et al. J Bone Miner Res. 2003;18:1051-1056.)
Thursday Sep 30, 2004
Pulsed IV Methylprednisolone Produces Significant Bone Loss, Short-Term Study Shows
Conventional wisdom holds that pulsed IV corticosteroids reduce the risk of bone loss. New findings show that even this treatment schedule is associated with significant reductions in bone mineral density...Haugeberg G et al. Ann Rheum Dis. 2004;63:940-944.
|
